Risk of severe asthma episodes predicted from fluctuation analysis of airway function

Asthma is an increasing health problem worldwide, but the long-term temporal pattern of clinical symptoms is not understood and predicting asthma episodes is not generally possible. We analyse the time series of peak expiratory flows, a standard measurement of airway function that has been assessed twice daily in a large asthmatic population during a long-term crossover clinical trial. Here we introduce an approach to predict the risk of worsening airflow obstruction by calculating the conditional probability that, given the current airway condition, a severe obstruction will occur within 30 days. We find that, compared with a placebo, a regular long-acting bronchodilator (salmeterol) that is widely used to improve asthma control decreases the risk of airway obstruction. Unexpectedly, however, a regular short-acting β2-agonist bronchodilator (albuterol) increases this risk. Furthermore, we find that the time series of peak expiratory flows show long-range correlations that change significantly with disease severity, approaching a random process with increased variability in the most severe cases. Using a nonlinear stochastic model, we show that both the increased variability and the loss of correlations augment the risk of unstable airway function. The characterization of fluctuations in airway function provides a quantitative basis for objective risk prediction of asthma episodes and for evaluating the effectiveness of therapy.

[1]  Samuel H. Wilson,et al.  Environmental health and genomics: visions and implications , 2000, Nature Reviews Genetics.

[2]  B. Suki,et al.  Temporal dynamics of recurrent airway symptoms and cellular random walk. , 2003, Journal of applied physiology.

[3]  D. Fabian,et al.  The global burden of asthma: executive summary of the GINA Dissemination Committee Report , 2004, Allergy.

[4]  W. Cookson,et al.  The alliance of genes and environment in asthma and allergy , 1999, Nature.

[5]  H. Bisgaard,et al.  Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. , 2005, American journal of respiratory and critical care medicine.

[6]  G. Town,et al.  Asthma control during long term treatment with regular inhaled salbutamol and salmeterol , 1998, Thorax.

[7]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[8]  B. Butland,et al.  Bronchodilator treatment and deaths from asthma: case-control study , 2004, BMJ : British Medical Journal.

[9]  S. Holgate,et al.  Variability and lack of predictive ability of asthma end-points in clinical trials , 2002, European Respiratory Journal.

[10]  Jeffrey M. Hausdorff,et al.  Long-range anticorrelations and non-Gaussian behavior of the heartbeat. , 1993, Physical review letters.

[11]  C. Picado,et al.  Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma , 2002, European Respiratory Journal.

[12]  S. Holgate Genetic and environmental interaction in allergy and asthma☆☆☆ , 1999, Journal of Allergy and Clinical Immunology.

[13]  B. Suki,et al.  Correlation properties of tidal volume and end-tidal O2 and CO2 concentrations in healthy infants. , 2002, Journal of applied physiology.

[14]  C. Print,et al.  Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. , 1993, Thorax.

[15]  J. Drazen,et al.  β-Agonists and asthma: too much of a good thing? , 2003 .

[16]  P. Macklem,et al.  Homeokinesis and short-term variability of human airway caliber. , 2001, Journal of applied physiology.

[17]  Andrew H. Liu,et al.  Self-Organized Patchiness in Asthma as a Prelude to Catastrophic Shifts , 2006, Pediatrics.